The basal cell nevus syndrome market is expected to witness steady growth driven by increasing awareness, advances in targeted therapies, and the development of novel hedgehog pathway inhibitors. Additionally, the expected launch of emerging therapies […]
The glomerulonephritis market is witnessing steady growth driven by the increasing prevalence of chronic kidney diseases and improved diagnostic capabilities. Additionally, ongoing clinical trial activities and the launch of emerging therapies such as lixudebart (Alentis […]
The glomerulonephritis market is witnessing steady growth driven by the increasing prevalence of chronic kidney diseases and improved diagnostic capabilities. Additionally, ongoing clinical trial activities and the launch of emerging therapies such as lixudebart (Alentis […]
The glomerulonephritis market is witnessing steady growth driven by the increasing prevalence of chronic kidney diseases and improved diagnostic capabilities. Additionally, ongoing clinical trial activities and the launch of emerging therapies such as lixudebart (Alentis […]
The indolent lymphoma market is witnessing steady growth driven by the increasing prevalence of slow-growing non-Hodgkin lymphomas and rising awareness about early diagnosis. Additionally, the launch of therapies such as AZD0486 (AstraZeneca), EO2463 (Enterome), Abexinostat […]
